Trial
NCT04746963
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
AsclepiX Therapeutics, Inc.
Collaborators
—
Condition
Neovascular Age-Related Macular Degeneration (nAMD)
Intervention
AXT107 0.1 mg
Why stopped
Adverse Events
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-22